Get the Stockscreener App
21.34
2.98%
0.5805
Hims Hers Health Inc stock is traded at $21.34, with a volume of 31.05M.
It is up +2.98% in the last 24 hours and up +21.05% over the past month.
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
See More
Previous Close:
$20.76
Open:
$22.08
24h Volume:
31.05M
Relative Volume:
3.09
Market Cap:
$4.49B
Revenue:
$1.07B
Net Income/Loss:
$18.10M
P/E Ratio:
-125.53
EPS:
-0.17
Net Cash Flow:
$89.50M
1W Performance:
-3.88%
1M Performance:
+21.05%
6M Performance:
+89.86%
1Y Performance:
+229.91%
1-Day Range:
$19.54
$22.28
1-Week Range:
$18.32
$22.28
52-Week Range:
$6.23
$25.74
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Industry
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health's (HIMS) "Neutral" Rating Reiterated at Piper Sandler - MarketBeat
Hims & Hers Stock Rises on Earnings, Generic Version of Novo Nordisk Diabetes Drug - Barron's
What's Going On With Hims & Hers Health Stock Tuesday? - Benzinga
Hims & Hers Health: Another Blowout Quarter Ignored (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (NYSE:HIMS) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Revenue Soars 77% for Hims & Hers Health, Inc. in Q3 2024 - Happi
Hims & Hers Stock Soars: First Generic Weight Loss Drug to Shake Up Billion-Dollar Market - GuruFocus.com
Hims & Hers Reports High Success Rate in GLP-1 Program - Athletech News
HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts - Yahoo Finance
Hims & Hers Health (HIMS) to Launch Generic Liraglutide for Weig - GuruFocus.com
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance - Barchart
Canaccord Genuity Group Increases Hims & Hers Health (NYSE:HIMS) Price Target to $28.00 - MarketBeat
Hims & Hers Health, Inc. (NYSE:HIMS) Q3 2024 Earnings Call Transcript - Insider Monkey
Hims & Hers to launch a generic for Novo’s older GLP-1 - MSN
Citi lifts Hims and Hers share price target on strong results - Investing.com
Hims and Hers stock gets boost from BofA as marketing spend fuels user growth - Investing.com
Hims & Hers defends compounded GLP-1s as shortages wane - Modern Healthcare
Earnings call: Hims & Hers reports robust Q3 growth, plans for expansion - Investing.com
Vanguard Group Inc's Strategic Acquisition in Hims & Hers Health Inc - GuruFocus.com
Hims & Hers Health Inc (HIMS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Expansion - GuruFocus.com
Hims & Hers Health Inc (HIMS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance UK
Hims & Hers Health Reports Strong Q3 2024 Growth - TipRanks
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow (HIMS) - Seeking Alpha
Hims & Hers Health Q3 earnings beat estimates, raises guidance - MSN
PLTR, DJT, HIMS, NXPI, TSLA: Top 5 Trending Stocks TodayHims & Hers Health (NYSE:HIMS), Trump Media & Technology (NASDAQ:DJT) - Benzinga
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’ - MSN
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates - MSN
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences. - Yahoo Finance
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025 - Reuters
Hims & Hers shares rally on results, despite continued GLP-1 drug shortage - MarketWatch
Hims & Hers Stock Up Ahead of Earnings: Retail Sentiment Upbeat - MSN
HIMS Q3 Estimates Unchanged Before Earnings: How to Play the Stock? - MSN
Hims & Hers up 7% on raised 2024 revenue guidance, Q3 beats - Seeking Alpha
Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details - Benzinga
Hims & Hers Health Raises Outlook, Swings to 3Q Profit - MarketWatch
Hims & Hers Health Q3 earnings beat estimates, raises guidance By Investing.com - Investing.com Canada
Hims & Hers Stock Up Ahead Of Earnings: Retail Sentiment Upbeat - Barchart
Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results - Business Wire
Decoding Hims & Hers Health's Options Activity: What's the Big Picture? - Benzinga
Hims & Hers Health Inc (HIMS) Shares Up 3.71% on Nov 4 - GuruFocus.com
Hims & Hers Health, Inc. (HIMS) Stock Moves -1.1%: What You Should Know - MSN
Hims & Hers Health Inc (HIMS) Shares Up 6.33% on Nov 1 - GuruFocus.com
Learn to Evaluate (HIMS) using the Charts - Stock Traders Daily
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lil - GuruFocus.com
Hims & Hers Health (NYSE:HIMS) Stock Price Up 7.5%Still a Buy? - MarketBeat
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance
36,840 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by International Assets Investment Management LLC - MarketBeat
What is Leerink Partnrs' Estimate for HIMS FY2024 Earnings? - MarketBeat
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why - Benzinga
Notable Wednesday Option Activity: HIMS, UAL, AMGN - Nasdaq
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update) - Seeking Alpha
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.23%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):